ELK GROVE VILLAGE, Illinois, Aug 28, 2026
Orsini announced that it will serve as a specialty pharmacy partner for Priovant Therapeutics’ LISRAYA™ (brepocitinib), an oral targeted therapy approved for the treatment of adults with dermatomyositis (DM). The partnership is intended to support patients as they access and begin treatment with LISRAYA, which the companies describe as the first FDA-approved targeted therapy for dermatomyositis. Orsini, a specialty pharmacy focused on rare diseases and advanced therapies, will provide pharmacy and patient-support services designed to help simplify access to the newly approved treatment. The announcement follows the regulatory milestone for LISRAYA and represents an important step in translating the therapy’s clinical development into patient access and ongoing treatment support.
Specialty Pharmacy Partnership Supports Patient Access
Under the partnership, Orsini will provide specialty pharmacy services for LISRAYA, leveraging its experience supporting patients receiving therapies for rare and complex diseases. Its integrated model includes pharmacy distribution, patient services, clinical management and home infusion services, with trained therapy care teams supporting patients and their families throughout treatment. For a rare autoimmune condition such as dermatomyositis, access and treatment coordination can be important components of the patient journey. Orsini said its role will focus on helping patients navigate access to LISRAYA and providing a coordinated experience following prescription and treatment initiation. The partnership with Priovant therefore connects the newly approved therapy with a specialty pharmacy infrastructure designed around complex and rare-disease treatment needs. The companies emphasized that the collaboration is intended to help patients gain a more seamless pathway to therapy following the FDA approval.
LISRAYA Targets Rare Autoimmune Dermatomyositis
LISRAYA (brepocitinib) is indicated for the treatment of adults with dermatomyositis, a rare autoimmune inflammatory disease associated with painful skin rashes and debilitating muscle weakness. The disease can also involve broader systemic complications, including lung, cardiac and gastrointestinal manifestations, potentially creating substantial challenges for affected patients. According to the announcement, LISRAYA was evaluated in the VALOR clinical study, described by the company as the largest placebo-controlled dermatomyositis trial conducted to date. Patients receiving LISRAYA demonstrated clinically meaningful improvements across several disease measures, including global myositis response, cutaneous disease, muscle strength, functional disability and steroid sparing. The treatment’s approval introduces a targeted therapeutic option for adults with dermatomyositis and expands the treatment landscape for a population that has historically had limited therapeutic choices. LISRAYA is administered as a once-daily oral therapy, providing an additional treatment format for eligible adult patients.
Advertisement
Safety Monitoring Remains Critical With LISRAYA
Because LISRAYA is a Janus kinase (JAK) inhibitor, its approved use includes important safety considerations that require appropriate clinical monitoring. The prescribing information carries a Boxed Warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis. Patients treated with LISRAYA may face increased risks of serious bacterial, fungal, viral and opportunistic infections, including tuberculosis and invasive fungal infections. Healthcare professionals are advised to evaluate patients for active and latent tuberculosis before and during treatment and to monitor for signs of infection. The prescribing information also warns about malignancies, cardiovascular events and thrombotic events, including deep vein thrombosis, pulmonary embolism and arterial thrombosis. Additional precautions include hypersensitivity, gastrointestinal perforation, hypoglycemia in patients with diabetes, laboratory abnormalities and embryofetal toxicity. LISRAYA is not recommended for patients with severe hepatic or severe renal impairment, and live vaccines should be avoided during or immediately before treatment initiation. These considerations underscore the importance of appropriate patient selection, safety assessment and ongoing monitoring during therapy. The specialty pharmacy partnership between Orsini and Priovant represents an important commercialization and patient-access development following the approval of LISRAYA. By combining Priovant’s targeted treatment with Orsini’s rare-disease pharmacy infrastructure, the companies aim to support adults living with dermatomyositis as they access and receive the newly approved therapy. Continued post-approval treatment experience will further contribute to understanding how LISRAYA is incorporated into real-world care for this rare autoimmune disease.
Source: Orsini press release
